Research

New discoveries in lung cancer research, such as the research funded by LCFA, are resulting in new treatments for lung cancer patients

How LCFA uses your donation wisely to fight lung cancer:

You Make A Donation to LCFA
Your dollars are added to contributions from other donors




We maximize your donation by adding it to dollars from LCFA’s strategic funding partners.


This leveraged donation allows LCFA to award a generous grant to a top young lung cancer investigator for 2 years of focused and intense research.


The lung cancer investigator
can now start the critical two-year process of research and discovery

Now, armed with this new evidence, the lung cancer investigator presents their findings to organizations like the National Institutes of Health (NIH) for consideration for vital next-stage grants.

Each painstaking step brings us closer to understanding how lung cancer works, how to detect it earlier, how to fight it better, and – someday – how to cure it.



Latest In Research

05/23
2018

Low Lung Cancer Screening Rate

from OncLive A total 1.9% of more than 7.6 million current and former heavy smokers in the United States underwent lung cancer screening in 2016, suggesting that it remains inadequate despite recommendations from the United States Preven…

05/22
2018

Immunotherapy Combination Increases Lung Cancer Survival

from WHTC Radio Roche's immunotherapy Tecentriq, given with its older drug Avastin and chemotherapy, improved survival of advanced lung cancer patients by about 30 percent over the combination without Tecentriq, according to interim resu…

05/22
2018

Testing for all lung cancer mutations at once found cost effective

From Reuters Testing advanced lung cancer patients for all of the possible genetic mutations that could be driving their cancer at once is more cost effective than testing for one or a limited number of genes at a time, U.S. researchers repo…

05/21
2018

Attention: Extensive-stage small cell lung cancer patients

Thoracic Oncology Translational Research April, 2018 Issue 61 Extensive-stage small cell lung cancer patients who have received no prior systemic treatment: Dr. Jonathan Goldman’s AZ CASPIAN trial is expected to complete enrollment of new…

05/1
2018

New liquid biopsy-based cancer model reveals data on deadly lung cancer

From EurekAlert Small cell lung cancer (SCLC) accounts for 14 percent of all lung cancers and is often rapidly resistant to chemotherapy resulting in poor clinical outcomes. Treatment has changed little for decades, but a study at The Un…

05/1
2018

What Is EGFR and How Does It Relate to Lung Cancer?

From US News For some patients, drugs targeting this genetic mutation may mean better results than chemotherapy. IN THE PAST SEVERAL years, our understanding of lung cancer has become much more detailed and nuanced. "When I started [pra…

04/26
2018

Immuno therapy scores big win against lung cancer in study

From StarTribune For the first time, a treatment that boosts the immune system greatly improved survival in people newly diagnosed with the most common form of lung cancer. It's the biggest win so far for immunotherapy, which has had muc…

04/26
2018

NSCLC with EGFR mutations gets new first-line treatment approved by FDA

From FDA.gov On April 18, 2018, the Food and Drug Administration approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals LP) for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors hav…

04/26
2018

ALK-positive non-small cell lung cancer gets boost from Lorlatinib

From Helio ALK-positive non-small cell lung cancer gets a boost when a new study shows that Lorlatinib demonstrated antitumor activity among patients with non-small cell lung cancer and ALK kinase domain mutations. Study results were present…

04/24
2018

Scientists identify 170 potential lung cancer drug targets

from Eureka Alert After testing more than 200,000 chemical compounds, UT Southwestern's Simmons Cancer Center researchers have identified 170 chemicals that are potential candidates for development into drug therapies for lung cancer. The…



Read More